TABLE 1.
Baseline characteristics of the case series.
| Total population n = 68 | Efficacy set n = 62 | |
| 57 (83.8) | 53 (85.5) | |
| Age, mean (SD), years | 31.9 (9.5) | 31.8 (8.4) |
| Time from PAH diagnosis to selexipag initiation | ||
| Mean (SD), years | 4.8 (4.9) | 4.8 (5.0) |
| PAH etiology, n (%) | ||
| IPAH | 42 (61.8) | 40 (64.5) |
| Post-operative CHD-PAH | 17 (25.0) | 15 (24.2) |
| CTD-PAH | 7 (10.3) | 6 (9.7) |
| HPAH | 2 (2.9) | 1 (1.6) |
| Combination of selexipag, n (%) | ||
| Third add-on to ERA and PDE5i combination | 50 (73.5) | 46 (74.2) |
| Transition from subcutaneous treprostinil to selexipag | 11 (16.2) | 10 (16.1) |
| Upfront triple combination in newly diagnosed PAH | 7 (10.3) | 6 (9.7) |
Continuous data are expressed as the “mean (SD).” IPAH, idiopathic pulmonary arterial hypertension; CHD-PAH, PAH associated with congenital heart disease; CTD-PAH, PAH associated with connective tissue diseases; HPAH, heritable PAH.